scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0959-8049(97)00175-5 |
P698 | PubMed publication ID | 9470834 |
P2093 | author name string | C Rekacewicz | |
J Jacob | |||
F Morvan | |||
P Rougier | |||
M Ducreux | |||
J F Seitz | |||
J M Tigaud | |||
B Paillot | |||
A LaPlanche | |||
M C Fabri | |||
M Luboinski | |||
P Laplaige | |||
S Grandjouan | |||
P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
Reporting results of cancer treatment | Q29620070 | ||
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma | Q34523575 | ||
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma | Q38207042 | ||
Estimation of confidence limits for the cumulative probability of survival in life table analysis | Q41897761 | ||
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study | Q44583571 | ||
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study | Q44664927 | ||
Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer | Q67591718 | ||
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma | Q68066794 | ||
Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay | Q70058382 | ||
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial | Q72732640 | ||
P433 | issue | 11 | |
P921 | main subject | colorectal cancer | Q188874 |
fluorouracil | Q238512 | ||
colorectal carcinoma | Q25493920 | ||
metastatic colon cancer | Q108566365 | ||
P304 | page(s) | 1789-1793 | |
P577 | publication date | 1997-10-01 | |
P1433 | published in | European Journal of Cancer | Q332260 |
P1476 | title | 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer | |
P478 | volume | 33 |
Q73898297 | Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma |
Q38081864 | Management of advanced colorectal cancer, Part 1. |
Q39392750 | MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers |
Q36178667 | Pre-operative radiochemotherapy of locally advanced rectal cancer |
Q44146804 | Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer |
Q35579304 | Radiotherapy and Oral Capecitabine in the Preoperative Treatment of Patients with Rectal Cancer: Rationale, Preliminary Results and Perspectives |
Q77632445 | Rational development of capecitabine |
Q26830695 | Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management |
Q34928276 | The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. |
Q34711507 | Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? |
Search more.